Cipla
-
Pharma stocks under pressure, tank over 10 per cent as Trump hints at 'never seen before' tariffs
Market | Apr 04, 2025, 11:42 AM ISTCipla Share Price, Sun Pharma Share Price: Earlier on Thursday, shares of pharma companies surged 7 per cent after the Trump administration exempted pharmaceuticals from reciprocal tariffs.
-
Cipla recalls six batches of bronchospasm treatment inhalation aerosol in US
World | Jul 07, 2023, 02:36 PM ISTOut of an abundance of precaution, Cipla further said the specified six batches manufactured using the same lot of valves are being recalled.
-
VIDEO: Cipla gets DCGI nod to import Modernas COVID vaccine
News | Jun 30, 2021, 08:15 AM ISTDrugs Controller General of India (DCGI) granted permission to Mumbai-based pharmaceutical firm Cipla to import Moderna COVID-19 vaccine for India.
-
Cipla gets DCGI nod to import Moderna's Covid vaccine for emergency use in India: Centre
India | Jun 29, 2021, 09:30 PM ISTMumbai-based pharmaceutical firm Cipla has received the Drugs Controller General of India (DCGI) nod to import Moderna’s COVID-19 vaccine for restricted emergency use in India, sources told news agency PTI.
-
Moderna seeks regulatory approval for Covid-19 vaccine in India; Cipla applies for import
India | Jun 29, 2021, 12:54 PM ISTModerna seeks regulatory approval for its COVID-19 vaccine in India. Cipla has also applied for authorisation to import and marketing of Moderna jabs in the country.
-
COVID: Cipla launches 'ViraGen' RT-PCR test
Business | May 20, 2021, 03:40 PM ISTViraGen is Cipla's third offering in the Covid testing segment. Cipla already has partnerships for antibody detection kit and antigen test kits.
-
Cipla inks pact with Eli Lilly to produce, sell COVID-19 treatment drug
Business | May 10, 2021, 11:56 AM ISTThis collaboration is a step further in the company's efforts to enhance access to critical treatments for patients affected by the pandemic, Cipla said in a statement.
-
Cipla launches antibody detection kit for coronavirus in India
Business | Oct 28, 2020, 07:29 PM ISTDrug firm Cipla on Wednesday announced the launch of antibody detection kits for COVID-19 in India under the brand name 'ELIFast' in partnership with KARWA Ltd, under the technology transfer from the Indian Council of Medical Research (ICMR).
-
Equity indices close in the green, Cipla gains 9.5 pc
News | Aug 10, 2020, 06:31 PM ISTEquity benchmark indices shaved off early gains but ended in the positive terrain on Monday with pharma stocks leading the rally.
-
Cipla Q1 net profit up 27 pc at Rs 566 cr
Business | Aug 07, 2020, 07:44 PM ISTDrug firm Cipla on Friday reported a 26.58 per cent rise in its consolidated net profit to Rs 566.04 crore for the quarter ended June on the back of robust sales.
-
Collaborating with govt agencies to develop treatment for COVID-19: Cipla
Business | Aug 05, 2020, 03:33 PM ISTBesides scaling up production of medicines that show potency against the virus -- Lopinavir + Ritonavir, Hydroxychloroquine and Azithromycin, the company is also ramping up manufacturing of drugs for chronic ailments such as asthma, COPD, among others, Hamied said.
-
Sensex cracks by 335 points but pharma stocks outperform
News | Jul 30, 2020, 06:56 PM ISTEquity benchmark indices swung nearly 1 per cent lower during the afternoon session on July 30 ahead of the expiry day of monthly futures and options contracts.
-
Hyderabad's Avra Labs to make Favipiravir for Cipla's Ciplenza
Business | Jul 27, 2020, 03:06 PM ISTHyderabad-based Avra Laboratories Pvt Ltd announced on Monday that it had received regulatory approval from the Central Drugs Standard Control Organisation (CDSCO) to manufacture and market Favipiravir Active Pharmaceutical Ingredient (API) for treatment of COVID-19.
-
Cipla gets nod to launch affordable Favipiravir in India for treatment of COVID-19 patients
India | Jul 24, 2020, 05:54 PM ISTPharmaceutical firm Cipla is set to launch COVID-19 drug Favipiravir, developed by the Council of Scientific and Industrial Research (CSIR) in a cost-effective process. Cipla has scaled up the process in their manufacturing facility and approached DCGI (Drug Controller General of India) for permission to launch the product in India.
-
Cipla, Amgen settle case involving generic cinacalcet hydrochloride tablets
Business | Jul 20, 2020, 11:43 AM ISTThe the civil action filed by Cipla in the U.S. District Court for the District of Delaware in January 2019 has been resolved as between Cipla and Amgen Inc, the drug major said on Monday (20 July).
-
Cipla launches generic version of remdesivir in India
Business | Jul 08, 2020, 09:24 PM ISTPharma major Cipla on Wednesday said it has launched its generic version of antiviral drug remdesivir at a price which is among the lowest globally and is looking to supply over 80,000 vials within the first month.
-
Cipla to price generic version of COVID-19 drug remdesivir at less than Rs 5,000 per vial
Business | Jun 23, 2020, 09:03 PM ISTPharma major Cipla will price its generic version of antiviral drug remdesivir at less than Rs 5,000 per vial in keeping with its conviction of providing access to the medicines at affordable cost, the company said on Tuesday.
-
Remdesiver, Favipiravir antiviral drugs 'no game changers' in COVID-19 fight, say medical experts
India | Jun 22, 2020, 11:06 PM ISTWith pharmaceutical companies launching generic versions of Remdesivir and Favipiravir for COVID-19 treatment, medical experts on Monday said it was a "positive development" in the fight against the pandemic, but cautioned against regarding the antiviral drugs as "game changers".
-
Cipremi: Cipla also launches COVID-19 treatment medicine, all you need to know
Fyi | Jun 22, 2020, 12:34 PM ISTCipla, an Indian multinational pharmaceutical and biotechnology company, has launched its own antiviral drug named Cipremi for treating COVID-19 patients.
-
Cipla launches generic remdesivir for COVID-19 patients
India | Jun 21, 2020, 11:28 PM ISTHomegrown pharma major Cipla Ltd announced the launch of its generic version of remdesivir, which has been authorised for emergency use in the treatment of COVID-19 patients by the USFDA, under its brand name Cipremi.